Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients with Heart Failure by Baseline Diabetes Status: Results from the EMPEROR-Reduced Trial

Authors :: Anker, S.D. Butler, J. Filippatos, G. Khan, M.S. Marx, N. Lam, C.S.P. Schnaidt, S. Ofstad, A.P. Brueckmann, M. Jamal, W. Bocchi, E.A. Ponikowski, P. Perrone, S.V. Januzzi, J.L. Verma, S. Böhm, M. Ferreira, J.P. Pocock, S.J. Zannad, F. Packer, M.
Publication Year :: 2021
Abstract: Background: Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with heart failure with reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on heart failure and renal events. Methods: Patients with Class II-IV heart failure and a left ventricular ejection fraction ≤40% were randomized to receive empagliflozin (10 mg daily) or placebo in addition to recommended therapy. We prespecified a comparison of the effect of empagliflozin in patients with and without diabetes. Results: Of the 3730 patients enrolled, 1856 (50%) had diabetes, 1268 (34%) had prediabetes (hemoglobin A1c [HbA1c] 5.7-6.4%), and 606 (16%) had normoglycemia (HbA1c

Tools